A Randomized, Controlled Phase III Trial of Sorafenib With or Without Conventional Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma (STAH Study)

Trial Profile

A Randomized, Controlled Phase III Trial of Sorafenib With or Without Conventional Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma (STAH Study)

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2018

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms STAH
  • Most Recent Events

    • 14 Apr 2018 Results presented at The International Liver Congress 2018
    • 27 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 05 Apr 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top